

Synthesis of differentially protected ribitol derivatives from 3,4-*O*-benzylidene-*D*-ribo-1,5-lactone

Dirk J. Lefeber,[†] Peter Steunenberg,
Johannes F. G. Vliгентhart and Johannes P. Kamerling*

Bijvoet Center, Department of Bio-Organic Chemistry, Utrecht University, Padualaan 8, NL-3584 CH Utrecht, The Netherlands

Received 12 November 2004; accepted 10 December 2004

Abstract—Several differentially protected ribitol derivatives were synthesised using 3,4-*O*-benzylidene-*D*-ribo-1,5-lactone as versatile starting compounds for oligosaccharide synthesis. The obtained ribitol derivatives allow the regiospecific coupling of glycosyl donors to either of the hydroxyl groups of ribitol and can be applied for the preparation of polyhydroxylated compounds.
© 2004 Elsevier Ltd. All rights reserved.


1. Introduction

Ribitol is a common monosaccharide constituent of many bacterial capsular polysaccharides, such as those from *Streptococcus pneumoniae* types 6, 10A and 13,¹ and from *Haemophilus influenzae* type b.² Since in polysaccharides different hydroxyl groups of ribitol may be involved in the glycosidic linkage, regiospecific protection strategies are required for the synthesis of ribitol-containing oligosaccharides. Furthermore, differently protected alditols are attractive synthetic intermediates for the preparation of various classes of polyhydroxylated compounds.³

In 1968 the product of the reaction of *D*-ribonolactone **1** (Scheme 1) with concentrated hydrochloric acid and

benzaldehyde was postulated to be 3,5-*O*-benzylidene-*D*-ribo-1,4-lactone **2**,⁴ and as such it was used by others.^{5,6} However, in 1985 crystallographic studies of the acetylated compound showed the reaction product to be 3,4-*O*-benzylidene-*D*-ribo-1,5-lactone **3** instead of the 3,5-*O*-acetal.⁷ The use of the 1,5-lactone has been described in the preparation of (2*R*,3*S*,4*R*)-dihydroxyproline⁸ and pyrrolidine derivatives.⁹

In the context of our synthetic studies on ribitol-containing oligosaccharide fragments of bacterial polysaccharides, herein we report easily accessible protocols for the preparation of three differentially protected ribitol derivatives starting from 3,4-*O*-benzylidene-*D*-ribo-1,5-lactone **3**: 3,4-*O*-benzylidene-*D*-ribitol **4**, 3,4-*O*-benzylidene-1-*O*-*tert*-butyldimethylsilyl-*D*-ribitol



Scheme 1. Reagents and conditions: (a) PhCHO, HCl, 87%; (b) NaBH₄, MeOH, THF, 55 °C, 85%.

* Corresponding author. Tel.: +31 30 253 34 79; fax: +31 30 254 09 80; e-mail: j.p.kamerling@chem.uu.nl

[†] Present address: Laboratory of Pediatrics and Neurology, Reinier Postlaan 4, 6525 GC Nijmegen, The Netherlands.

6, and 3-*O*-allyl-2-*O*-*tert*-butyldimethylsilyl-5-*O*-*tert*-butyldiphenylsilyl-*D*-ribose **10**.


2. Results and discussion

Key compound 3,4-*O*-benzylidene-*D*-ribo-1,5-lactone **3** (Scheme 1) was prepared by reaction of *D*-ribo-1,4-lactone **1** with benzaldehyde and concentrated HCl in 87% yield. ¹H NMR analysis of acetylated **3** showed a downfield shifted H-2 (δ 5.53 ppm, d, $J_{2,3}$ 3.2 Hz), a benzylidene proton at δ 5.81 ppm, characteristic for an acetal proton in a 1,3-dioxolane ring system, and a ROESY contact between H-3 and H-4, in agreement with the orientation of H-3 and H-4 in compound **3** (*cis*), but not in compound **2**. Opening and reduction of lactone **3** by using sodium borohydride and methanol in tetrahydrofuran afforded **4** in a yield of 85%. ¹H NMR analysis of the acetylated product showed a downfield shifted H-2 (δ 5.16 ppm, ddd), and an acetal proton at δ 5.84 ppm, which is evidence for a benzylidene group in a 5-membered ring. Ribitol derivative **4** can be used for coupling at *O*-2 after protection of the primary hydroxyl groups, if no selectivity of the primary hydroxyl groups is required.


For the preparation of ribitol derivative **6** (Scheme 2), compound **3** was silylated with *tert*-butyldimethylsilyl (TBDMS) chloride¹⁰ to afford **5** in 95% yield. The position of the acetal proton in the ¹H NMR spectrum (δ 5.71 ppm) indicated a benzylidene group in a 1,3-dioxolane ring system, and the chemical shifts of C-3 and C-4 in the ¹³C NMR spectrum (range δ 73–77 ppm⁸) indicated a 1,5-lactone. Reduction of **5** using sodium borohydride and methanol in tetrahydrofuran afforded **6** as the only product in 86% yield. The identity of **6** was derived from the ¹H NMR analysis of the acetylated

product. First of all, two acetyl groups, a benzylidene group and a *tert*-butyldimethylsilyl group are present. A downfield shifted H-2 was shown (δ 5.01 ppm, ddd), which corresponds to an acetylated *O*-2, thereby indicating the migration of the silyl group from *O*-2 to *O*-1. Furthermore, a comparison of the H-1 chemical shifts in acetylated **6** with acetylated **4** (Scheme 1) showed an upfield shift from >4.10 to 3.93 and 3.84 ppm, supporting that *O*-1 is not acetylated in **6**. The position of the acetal proton at δ 5.84 ppm indicated that the 1,3-dioxolane ring system was intact. A similar silyl migration under reducing conditions with sodium borohydride has been observed before.¹¹ Thus, due to a facile silyl migration, ribitol derivative **6** is obtained, which can be used for reactions at *O*-2 with the option of selective protection of the primary hydroxyl functions.

The synthesis of a ribitol derivative in which *O*-3 and *O*-4 are selectively accessible, was started from *D*-ribonolactone derivative **5** (Scheme 3). Debenzylidenation of **5** without affecting the silyl group was accomplished by catalytic hydrogenation using a palladium catalyst in ethyl acetate, affording **7** in 97% yield. It should be noted that hydrogenation of **5** in ethanol led to cleavage of the silyl group. The cleavage of a *tert*-butyldimethylsilyl group has been described before during a transfer hydrogenation in methanol.¹² The identity of **7** was confirmed by NMR analysis. The position of C-4 in the ¹³C NMR spectrum of **7** (δ 84.6 ppm) is characteristic for a 1,4-lactone; the ¹H NMR spectrum of acetylated **7** showed a downfield shifted H-3 (δ 5.31 ppm, dd) and a non-*O*-acetylated *O*-4 (δ 4.65 ppm, m). A similar rearrangement of a ribono-1,5-lactone to a ribono-1,4-lactone after debenzylation with trifluoroacetic acid had been found previously.⁸ For the selective protection of *O*-5 in **7**, the *tert*-butyldiphenylsilyl (TBDPS) group was chosen,¹³ and reaction of **7** with *tert*-butyldiphenylsilyl



Scheme 2. Reagents and conditions: (a) TBDMSCl, C₅H₅N, DMAP, 95%; (b) NaBH₄, MeOH, THF, 55 °C, 86%.



Scheme 3. Reagents and conditions: (a) H₂, 10% Pd/C, EtOAc, 97%; (b) TBDPSCl, CH₂Cl₂, C₅H₅N, DMAP, 80%; (c) (i) AcCl, CH₂Cl₂, C₅H₅N, 0 °C, 84%, (ii) (PPh₃)₄Pd(0), CH₃CN, He, 55 °C, 75%; (d) NaBH₄, MeOH, THF, 55 °C, 86%.

chloride¹⁴ gave **8** in 80% yield. The remaining hydroxyl function at C-3 was chosen to be allylated. Sodium hydride-mediated allylation of **8** turned out to be impossible due to opening of the base-labile lactone. Therefore, a two-step allylation procedure was used.¹⁵ Allyloxy-carbonylation and subsequent decarboxylation using tetrakis-triphenylphosphine-palladium(0) gave **9** in 63% yield. Reductive opening of the lactone using sodium borohydride and methanol in tetrahydrofuran afforded the ribitol derivative **10** in a yield of 86%. The ¹H NMR spectrum of acetylated **10** showed a downfield shifted H-4 (δ 5.23, dt), and the presence of two acetyl groups, a TBDMS group, a TBDPS group and an allyl group. The resulting ribitol derivative **10** allows the glycosidic coupling to either of the skeleton oxygen atoms.

3. Conclusion

3,4-*O*-Benzylidene-D-ribo-1,5-lactone has been shown to be a versatile compound for the preparation of several differentially protected ribitol derivatives. These products can be used for the regiospecific coupling of protected sugar donors to one of the hydroxyl groups of ribitol or for the preparation of polyhydroxylated compounds.

4. Experimental

4.1. General methods

All reagents were used as obtained commercially, without any further purification. Reactions were monitored by TLC on Kieselgel 60 F₂₅₄ (Merck); compounds were visualised, after examination under UV light, by charring with phenol–sulfuric acid or KMnO₄ and Na₂CO₃ in water. In the work-up procedures of reaction mixtures, organic solutions were washed with appropriate amounts of the indicated aqueous solutions, then dried over MgSO₄ and concentrated under reduced pressure at 20–40 °C on a water bath. Column chromatography was performed on Kieselgel 60 F₂₅₄ (Merck, 70–230 mesh). Optical rotations were measured in CHCl₃ with a Perkin–Elmer 241 polarimeter, using a 10-cm 1-mL cell. ¹H NMR spectra were recorded at 27 °C with a Bruker AC 300 spectrometer; the values of δ_{H} are given in ppm relative to the signal for internal Me₄Si (δ 0) for solutions in CDCl₃. ¹³C (APT, 75 MHz) NMR spectra were recorded at 27 °C with a Bruker AC 300 spectrometer; indicated ppm values for δ_{C} are relative to the signal of CDCl₃ (δ 76.9) for solutions in CDCl₃. Two-dimensional ¹H–¹H correlation spectra (TOCSY and ROESY) were recorded using a Bruker AMX 500 apparatus (500 MHz) at 27 °C. Elemental analyses were carried out by H. Kolbe Mikroanalytisches Laboratorium (Mülheim an der Ruhr, Germany).

4.2. 3,4-*O*-Benzylidene-D-ribitol, **4**

To a solution of D-ribo-1,4-lactone **1** (5.56 g, 38 mmol) in benzaldehyde (50 mL) was added concentrated HCl (5 mL). After 7 h, Et₂O (60 mL) was added,

and the precipitate collected by filtration. The residue was washed with aq 10% NaHCO₃ and water, and recrystallised from refluxing acetone, yielding **3** (7.75 g, 87%). ¹H NMR (DMSO-*d*₆): δ 7.46–7.32 (m, 5H, *PhCH*), 5.74 (s, 1H, *PhCH*), 4.69 (dd, 1H, $J_{3,4}$ 8.0, $J_{2,3}$ 3.2 Hz, H-3), 4.64 (br d, 1H, $J_{4,5b}$ 1.6 Hz, H-4), 4.62 (d, 1H, H-2), 4.42 (dd, 1H, $J_{5a,5b}$ 13.1 Hz, H-5b), 4.32 (d, 1H, H-5a); ¹H NMR (CDCl₃ + MeOH-*d*₃): δ 7.47–7.39 (m, 5H, *PhCH*), 5.81 (s, 1H, *PhCH*), 4.84 (dd, 1H, $J_{3,4}$ 8.1, $J_{2,3}$ 3.3 Hz, H-3), 4.69 (m, 1H, H-4), 4.56 (d, 1H, H-2), 4.39 (dd, 1H, $J_{5a,5b}$ 13.2 Hz, H-5). For further analysis, a small amount of **3** was acetylated with Ac₂O in pyridine. ¹H NMR (CDCl₃): δ 7.47–7.39 (m, 5H, *PhCH*), 5.81 (s, 1H, *PhCH*), 5.53 (d, 1H, $J_{2,3}$ 3.2 Hz, H-2), 4.84 (dd, 1H, $J_{3,4}$ 8.0 Hz, H-3), 4.69 (br d, 1H, H-4), 4.59 (d, 1H, $J_{5a,5b}$ 13.4 Hz, H-5a), 4.38 (dd, 1H, $J_{4,5b}$ 1.7 Hz, H-5b), 2.25 (s, 3H, CH₃CO).

To a solution of **3** (200 mg, 0.85 mmol) in THF (2.5 mL) was added NaBH₄ (80 mg). The mixture was heated to 55 °C, and MeOH (0.8 mL) was added dropwise over 30 min. After 1 h, TLC (95:5 CH₂Cl₂–MeOH) showed complete conversion of **3** into **4** (R_{f} 0.45). Then, the mixture was quenched by addition of HOAc, and coconcentrated with MeOH. The crude product was purified by column chromatography (98:2 CH₂Cl₂–MeOH) to yield **4** (170 mg, 85%). For analysis, a small aliquot was acetylated with Ac₂O in pyridine. ¹H NMR (CDCl₃): δ 7.49–7.37 (m, 5H, *PhCH*), 5.84 (s, 1H, *PhCH*), 5.16 (ddd, 1H, H-2), 2.08, 2.07 and 2.06 (3 s, each 3H, CH₃CO).

4.3. 3,4-*O*-Benzylidene-2-*O*-*tert*-butyldimethylsilyl-D-ribo-1,5-lactone, **5**

To a solution of **3** (7.75 g, 33 mmol) in pyridine (60 mL) at 0 °C were added TBDMSCl (7.7 g, 50 mmol) and a catalytic amount of DMAP. The mixture was allowed to reach room temperature, and after 20 h, a second portion of TBDMSCl (2.0 g, 13 mmol) was added. After 25 h, TLC (95:5 CH₂Cl₂–MeOH) showed complete conversion of **3** into **5**. The mixture was diluted with EtOAc, washed with aq 10% NaHCO₃ and aq 10% NaCl, and the organic layer dried, filtered and concentrated. Column chromatography (7:3 toluene–EtOAc) of the residue afforded **5** as a white solid (11.0 g, 95%). [α]_D = –134 (*c* 0.9, CHCl₃); R_{f} 0.89 (95:5 CH₂Cl₂–MeOH); ¹H NMR (CDCl₃): δ 7.47–7.33 (m, 5H, *PhCH*), 5.71 (s, 1H, *PhCH*), 4.64 (dd, 1H, $J_{2,3}$ 3.2, $J_{3,4}$ 8.0 Hz, H-3), 4.51 (dd, 1H, $J_{4,5b}$ 1.4 Hz, H-4), 4.45 (d, 1H, H-2), 4.36 (d, 1H, $J_{5a,5b}$ 13.4 Hz, H-5a), 4.15 (dd, 1H, H-5b), 0.94 (s, 9H, SiC(CH₃)₃), 0.20 and 0.13 (2 s, each 3H, Si(CH₃)₂); ¹³C NMR (CDCl₃): δ 169.4 (C-1), 135.1, 129.8, 128.2 and 127.2 (*PhCH*), 104.1 (*PhCH*), 77.3, 73.1 and 69.6 (C-2, C-3, C-4), 67.0 (C-5), 25.6 (SiC(CH₃)₃), 18.2 (SiC(CH₃)₃). Anal. Calcd for C₁₈H₂₆O₅Si (350.5): C, 61.69; H, 7.48. Found: C, 61.80; H, 7.47.

4.4. 3,4-*O*-Benzylidene-1-*O*-*tert*-butyldimethylsilyl-D-ribitol, **6**

To a solution of **5** (491 mg, 1.4 mmol) in dry THF (5 mL) was added NaBH₄ (130 mg). The mixture was

heated to 55 °C, and MeOH added dropwise over 30 min. After 1 h, TLC (95:5 CH₂Cl₂–MeOH) showed complete conversion of **5** into **6** (*R*_f 0.76). Then, the mixture was quenched with HOAc and coconcentrated with MeOH and toluene. The residue was purified by column chromatography (7:3 toluene–EtOAc) to yield **6** (400 mg, 86%). For analysis, a small amount of **6** was acetylated with Ac₂O in pyridine. ¹H NMR (CDCl₃): δ 7.48–7.37 (m, 5H, *Ph*CH), 5.84 (s, 1H, *Ph*CH), 5.01 (ddd, 1H, *J*_{2,3} 8.3, *J*_{1a,2} 2.7, *J*_{1b,2} 3.8 Hz, H-2), 4.52 (dd, 1H, *J*_{3,4} 6.1 Hz, H-3), 4.49–4.42 (m, 2H, H-4 and H-5), 4.08 (dd, 1H, *J*_{5a,5b} 12.8 Hz, H-5), 3.93 (dd, 1H, *J*_{1a,1b} 11.5 Hz, H-1a), 3.84 (dd, 1H, H-1b), 2.09 and 2.05 (2 s, each 3H, CH₃CO), 0.88 (s, 9H, SiC(CH₃)₃), 0.03 (s, 6H, Si(CH₃)₂).

4.5. 2-*O*-*tert*-Butyldimethylsilyl-D-ribo-1,4-lactone, **7**

A solution of **5** (10.8 g, 31 mmol) in EtOAc (150 mL), containing 10% Pd/C (2.5 g), was hydrogenated for 6 h, then the mixture filtered over Celite and concentrated. The residue was dissolved in EtOAc (150 mL), 10% Pd/C (1.5 g) was added and the suspension subjected to a second hydrogenation. After 2 h, the mixture was filtered over Celite and concentrated. The crude product was purified by column chromatography (95:5 CH₂Cl₂–MeOH) to obtain **7** as a white solid (8.0 g, 97%). [α]_D = +24 (*c* 1.4, MeOH); *R*_f 0.64 (95:5 CH₂Cl₂–MeOH); ¹H NMR (CDCl₃): δ 4.68 (d, 1H, *J*_{2,3} 5.5 Hz, H-2), 4.47 (m, 1H, *J*_{3,4} 0.9, *J*_{4,5a} 2.4, *J*_{4,5b} 2.6 Hz, H-4), 4.31 (ddd, 1H, *J*_{3,OH} 1.8 Hz, H-3), 3.97 (ddd, 1H, *J*_{5a,5b} 12.6, H-5b), 3.79 (ddd, 1H, H-5a), 0.94 (s, 9H, SiC(CH₃)₃), 0.23 and 0.20 (2 s, each 3H, Si(CH₃)₂); ¹³C NMR (CDCl₃): δ 170.5 (C-1), 84.6, 70.4 and 69.9 (C-2, C-3, C-4), 61.6 (C-5), 25.5 (SiC(CH₃)₃), 18.1 (SiC(CH₃)₃). Anal. Calcd for C₁₁H₂₂O₅Si (262.4): C, 50.36; H, 8.45. Found: C, 51.43; H, 8.53. For further analysis, a small amount of **7** was acetylated with Ac₂O in pyridine. ¹H NMR (CDCl₃): δ 5.31 (dd, 1H, *J*_{2,3} 5.9, *J*_{3,4} 2.0 Hz, H-3), 4.64 (m, 1H, *J*_{4,5a} 3.4, *J*_{4,5b} 3.9 Hz, H-4), 4.59 (d, 1H, H-2), 4.38 (dd, 1H, *J*_{5a,5b} 12.6 Hz, H-5a), 4.24 (dd, 1H, H-5b), 2.12 and 2.10 (2 s, each 3H, CH₃CO), 0.91 (s, 9H, SiC(CH₃)₃), 0.20 and 0.13 (2 s, each 3H, Si(CH₃)₂).

4.6. 2-*O*-*tert*-Butyldimethylsilyl-5-*O*-*tert*-butyldiphenylsilyl-D-ribo-1,4-lactone, **8**

To a solution of **7** (3.5 g, 14 mmol) in CH₂Cl₂ (66 mL) and pyridine (4.4 mL) were added TBDPSCI (4.1 mL, 15 mmol) and Et₃N (1.0 mL). After 16 h, the mixture was quenched with ice, diluted with CH₂Cl₂, washed with 10% aq NaHCO₃, dried, filtered and concentrated. The residue was purified by column chromatography (9:1 toluene–EtOAc) to afford **8** (5.4 g, 80%). [α]_D = +17 (*c* 1, CHCl₃); *R*_f 0.54 (9:1 toluene–EtOAc); ¹H NMR (CDCl₃): δ 7.71–7.67, 7.39–7.31 (2 m, 10H, *Ph*₂Si), 4.82 (d, 1H, *J*_{2,3} 5.6 Hz, H-2), 4.34 (m, 1H, *J*_{3,4} 1.2, *J*_{4,5a} 1.7, *J*_{4,5b} 2.4 Hz, H-4), 4.28 (dd, 1H, H-3), 3.82 (dd, 1H, *J*_{5a,5b} 11.8 Hz, H-5a), 3.64 (dd, 1H, H-5b), 1.04 (s, 9H, (Ph)₂SiC(CH₃)₃), 0.93 (s, 9H, (CH₃)₂SiC(CH₃)₃), 0.23 and 0.17 (2 s, each 3H, Si(CH₃)₂); ¹³C NMR (CDCl₃): δ 174.4 (C-1),

135.4–127.5 ((Ph)₂SiC(CH₃)₃), 84.2, 70.3 and 69.9 (C-2, C-3, C-4), 63.4 (C-5), 26.5 ((Ph)₂SiC(CH₃)₃), 25.2 ((CH₃)₂SiC(CH₃)₃), 18.8 ((Ph)₂SiC(CH₃)₃), 18.1 ((CH₃)₂SiC(CH₃)₃). Anal. Calcd for C₂₇H₄₀O₅Si₂ (500.8): C, 64.76; H, 8.05. Found: C, 65.01; H, 7.98.

4.7. 3-*O*-Allyl-2-*O*-*tert*-butyldimethylsilyl-5-*O*-*tert*-butyldiphenylsilyl-D-ribo-1,4-lactone, **9**

A stirred solution of **8** (3.5 g, 7.0 mmol) in dry acetonitrile (3.3 mL) and dry pyridine (1.1 mL) was cooled to 0 °C. Allyl chloroformate (1.46 mL, 14 mmol) in dry acetonitrile (3.3 mL) was added dropwise over 45 min, and stirring at 0 °C continued for 1 h. Then, TLC (9:1 toluene–EtOAc) showed complete conversion of **8** into **9** (*R*_f 0.83). After hydrolysing the remaining allyl chloroformate by addition of ice, the mixture was diluted with EtOAc, washed with water, dried, filtered and concentrated. The residue was purified by column chromatography (toluene) (3.4 g, 84%). [α]_D = +27 (*c* 1, CHCl₃); ¹H NMR (CDCl₃): δ 7.66–7.61, 7.44–7.38 (2 m, 10H, *Ph*₂Si), 5.97–5.84 (m, 1H, CH₂–CH=CH₂), 5.39 (br d, 1H, *J*_{2,3} 6.0, *J*_{3,4} < 1.0 Hz, H-3), 5.38–5.31, 5.27–5.22 (2 m, each 1H, CH₂–CH=CH₂), 4.88 (d, 1H, H-2), 4.69–4.56 (m, 2H, CH₂–CH=CH₂), 4.47 (m, 1H, *J*_{4,5a} 1.8, *J*_{4,5b} 2.5 Hz, H-4), 3.91 (dd, 1H, *J*_{5a,5b} 11.8 Hz, H-5b), 3.80 (dd, 1H, H-5a), 1.06 (s, 9H, (Ph)₂SiC(CH₃)₃), 0.93 (s, 9H, (CH₃)₂SiC(CH₃)₃), 0.21 and 0.14 (2 s, each 3H, Si(CH₃)₂); ¹³C NMR (CDCl₃): δ 173.5 (C-1), 153.8 (CO–CH₂–CH=CH₂), 135.3–127.8 ((Ph)₂SiC(CH₃)₃), 119.1 (CH₂–CH=CH₂), 81.4, 74.8, 68.8 (C-2, C-3, C-4), 68.6 (CH₂–CH=CH₂), 63.3 (C-5), 26.6 ((Ph)₂SiC(CH₃)₃), 25.3 ((CH₃)₂SiC(CH₃)₃), 18.9 ((Ph)₂SiC(CH₃)₃), 18.0 ((CH₃)₂SiC(CH₃)₃). Anal. Calcd for C₃₁H₄₄O₇Si₂ (584.86): C, 63.66; H, 7.58. Found: C, 63.69; H, 7.70.

The allyloxycarbonylated product (2.4 g, 4.1 mmol) was concentrated twice with dry THF, then dissolved in dry THF (10 mL) and purged with helium. After the addition of a catalytic amount of yellow tetrakis-triphenylphosphine-palladium(0), the mixture was heated to 55 °C on an oil bath. After 20 min, when TLC (8:2 toluene–EtOAc) showed complete conversion into **9** (*R*_f 0.67), the mixture was coconcentrated with toluene. The residue was purified by column chromatography (4:6 hexane–toluene, then toluene) to yield **9** as a sirup (1.2 g, 75%). [α]_D = +35 (*c* 1.3, CHCl₃); ¹H NMR (CDCl₃): δ 7.65–7.61, 7.46–7.38 (2 m, 10H, *Ph*₂Si), 5.96–5.87 (m, 1H, CH₂–CH=CH₂), 5.34–5.28, 5.22–5.18 (2 m, each 1H, CH₂–CH=CH₂), 4.20 (dd, 1H, *J*_{2,3} 5.4, *J*_{3,4} 1.4 Hz, H-3), 4.36 (d, 1H, H-2), 4.39–4.31, 4.25–4.18 (2 m, each 1H, CH₂–CH=CH₂), 3.87 (dd, 1H, *J*_{4,5a} 2.5, *J*_{4,5b} 11.8 Hz, H-5a), 3.76 (dd, 1H, *J*_{4,5b} 3.4 Hz, H-5b), 1.05 (s, 9H, (Ph)₂SiC(CH₃)₃), 0.87 (s, 9H, (CH₃)₂SiC(CH₃)₃), 0.09 and 0.06 (2 s, each 3H, Si(CH₃)₂); ¹³C NMR (CDCl₃): δ 173.5 (C-1), 133.7 (CH₂–CH=CH₂), 135.3–127.8 ((Ph)₂SiC(CH₃)₃), 118.1 (CH₂–CH=CH₂), 85.6, 74.4 and 70.5 (C-2, C-3, C-4), 71.6 (CH₂–CH=CH₂), 62.7 (C-5), 26.7 ((Ph)₂SiC(CH₃)₃), 25.5 ((CH₃)₂SiC(CH₃)₃), 18.8 ((Ph)₂SiC(CH₃)₃), 18.0 ((CH₃)₂SiC(CH₃)₃). Anal. Calcd for C₃₀H₄₄O₅Si₂ (540.8): C, 66.62; H, 8.20. Found: C, 66.65; H, 8.15.

4.8. 3-*O*-Allyl-2-*O*-*tert*-butyldimethylsilyl-5-*O*-*tert*-butyldiphenylsilyl-D-ribose, **10**

To a solution of **9** (700 mg, 1.28 mmol) in THF (7 mL) was added NaBH₄ (100 mg), and the mixture heated to 55 °C. A few drops of MeOH were added, and after 1 h, TLC (9:1 toluene–EtOAc) showed complete conversion of **9** into **10** (*R*_f 0.21). The mixture was diluted with MeOH, quenched with HOAc and coconcentrated with toluene. The residue was purified by column chromatography (95:5 toluene–EtOAc) to yield **10** (600 mg, 86%). [α]_D = –6 (*c* 0.8, CHCl₃); ¹H NMR (CDCl₃): δ 7.66–7.40 (m, 10H, Ph₂Si), 5.93–5.80 (m, 1H, CH₂–CH=CH₂), 5.26–5.11 (m, 2H, CH₂–CH=CH₂), 4.04–4.02 (m, 2H, CH₂–CH=CH₂), 1.08 (s, 9H, (Ph)₂SiC(CH₃)₃), 0.77 (s, 9H, (CH₃)₂SiC(CH₃)₃), 0.06 and –0.06 (2 s, each 3H, Si(CH₃)₂). ¹³C NMR (CDCl₃): δ 135.4–127.8 ((Ph)₂SiC(CH₃)₃), 134.6 (CH₂–CH=CH₂), 116.9 (CH₂–CH=CH₂), 79.7, 73.5 and 72.6 (C-2, C-3, C-4), 70.9 (CH₂–CH=CH₂), 65.3 and 60.9 (C-5, C-1), 26.8 ((Ph)₂SiC(CH₃)₃), 25.7 ((CH₃)₂SiC(CH₃)₃), 19.1 ((Ph)₂SiC(CH₃)₃), 17.9 ((CH₃)₂SiC(CH₃)₃). Anal. Calcd for C₃₀H₄₈O₅Si₂ (544.8): C, 66.13; H, 8.88. Found: C, 66.16; H, 8.84. For further analysis, a small amount of **10** was acetylated with Ac₂O in pyridine. ¹H NMR (CDCl₃): δ 7.66–7.40 (m, 10H, Ph₂Si), 5.90–5.77 (m, 1H, CH₂–CH=CH₂), 5.26–5.10 (m, 2H, CH₂–CH=CH₂), 5.23 (m, 1H, *J*_{3,4} 4.2, *J*_{4,5a} 4.1, *J*_{4,5b} 6.7 Hz, H-4), 4.39 (dd, 1H, *J*_{1a,1b} 11.9, *J*_{1a,2} 3.5 Hz, H-1a), 4.05 (dd, 1H, *J*_{2,3} 5.3 Hz, H-3), 3.89 (dd, 1H, *J*_{5a,5b} 11.0 Hz, H-5a), 3.80 (dd, 1H, H-5b), 3.58 (m, 1H, H-2), 2.12 and 2.10 (2 s, each 3H, CH₃CO), 1.08 (s, 9H (Ph)₂SiC(CH₃)₃), 0.77 (s, 9H, (CH₃)₂SiC(CH₃)₃), 0.06 and –0.06 (2 s, each 3H, Si(CH₃)₂).

Acknowledgements

This work was supported by the European Union program VACNET (grant ERB BIO 4CT960158).

References

1. Kamerling, J. P. Pneumococcal Polysaccharides: A Chemical View. In *Molecular Biology and Mechanisms of Disease. Streptococcus pneumoniae*; Thomasz, A., Ed.; Mary Ann Liebert, Inc.: New York, 2000; pp 81–114.
2. Egan, W.; Schneerson, R.; Werner, K. E.; Zon, G. *J. Am. Chem. Soc.* **1982**, *104*, 2898–2910.
3. Fleet, G. W. J.; Son, J. C. *Tetrahedron* **1988**, *44*, 2637–2647.
4. Zinner, H.; Voigt, H.; Voigt, J. *Carbohydr. Res.* **1968**, *7*, 38–55.
5. Chen, S.-Y.; Jouillié, M. M. *J. Org. Chem.* **1984**, *49*, 2168–2174.
6. Shah, R. H. *J. Carbohydr. Chem.* **1986**, *5*, 139–146.
7. Baggett, N.; Buchanan, J. G.; Fatah, M. Y.; Lachut, C. H.; McCullough, K. J.; Webber, J. M. *Chem. Commun.* **1985**, *24*, 1826–1827.
8. Dho, J. C.; Fleet, G. W. J.; Peach, J. M.; Prout, K.; Smith, P. W. *Tetrahedron Lett.* **1986**, *27*, 3203–3204.
9. Ikota, N.; Hanaki, A. *Chem. Pharm. Bull.* **1988**, *36*, 1143–1146.
10. Corey, E. J.; Venkateswarlu, A. *J. Am. Chem. Soc.* **1972**, *94*, 6190–6191.
11. Masaguer, C. F.; Blériot, Y.; Charlwood, J.; Winchester, B. G.; Fleet, G. W. J. *Tetrahedron* **1997**, *53*, 15147–15156.
12. Cormier, J. F. *Tetrahedron Lett.* **1991**, *32*, 187–188.
13. Nelson, T. D.; Crouch, R. D. *Synthesis* **1996**, 1031–1069.
14. Hanessian, S.; Lavalley, P. *Can. J. Chem.* **1975**, *53*, 2975–2977.
15. Guibe, F.; Saint M'leux, Y. *Tetrahedron Lett.* **1981**, *22*, 3591–3594.